Your browser doesn't support javascript.
loading
Nanoparticles crossing blood-brain barrier need specific design for normal, neurodegenerative or cancerous brain conditions.
Ljubimova, Julia Y; Holler, Eggehard; Black, Keith L; Ljubimov, Alexander V.
Affiliation
  • Ljubimova JY; Terasaki Institute for Biomedical Innovation, Los Angeles, CA 90024, USA.
  • Holler E; Terasaki Institute for Biomedical Innovation, Los Angeles, CA 90024, USA.
  • Black KL; Institut für Biophysik und Physikalische Biochemie Universtität, Regensburg, D-93040, Regensburg, Germany.
  • Ljubimov AV; Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Nanomedicine (Lond) ; 19(23): 1863-1866, 2024.
Article in En | MEDLINE | ID: mdl-39109486
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / Blood-Brain Barrier / Nanoparticles Limits: Animals / Humans Language: En Journal: Nanomedicine (Lond) Year: 2024 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / Blood-Brain Barrier / Nanoparticles Limits: Animals / Humans Language: En Journal: Nanomedicine (Lond) Year: 2024 Document type: Article Affiliation country: Country of publication: